- Home
- HALO vs LNTH Comparison
HALO vs LNTH Comparison
Compare HALO & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HALO
- LNTH
- Stock Information
- Founded
- HALO 1998
- LNTH 1956
- Country
- HALO United States
- LNTH United States
- Employees
- HALO N/A
- LNTH N/A
- Industry
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- HALO Health Care
- LNTH Health Care
- Exchange
- HALO Nasdaq
- LNTH Nasdaq
- Market Cap
- HALO 7.4B
- LNTH 7.5B
- IPO Year
- HALO N/A
- LNTH 2015
- Fundamental
- Price
- HALO $52.02
- LNTH $81.24
- Analyst Decision
- HALO Buy
- LNTH Strong Buy
- Analyst Count
- HALO 9
- LNTH 5
- Target Price
- HALO $63.56
- LNTH $133.80
- AVG Volume (30 Days)
- HALO 3.1M
- LNTH 1.4M
- Earning Date
- HALO 05-06-2025
- LNTH 05-07-2025
- Dividend Yield
- HALO N/A
- LNTH N/A
- EPS Growth
- HALO 55.40
- LNTH N/A
- EPS
- HALO 3.76
- LNTH 3.53
- Revenue
- HALO $1,084,306,000.00
- LNTH $1,536,699,000.00
- Revenue This Year
- HALO $24.79
- LNTH $4.96
- Revenue Next Year
- HALO $22.65
- LNTH $10.25
- P/E Ratio
- HALO $13.83
- LNTH $23.00
- Revenue Growth
- HALO 25.64
- LNTH 12.53
- 52 Week Low
- HALO $41.28
- LNTH $74.34
- 52 Week High
- HALO $70.51
- LNTH $126.89
- Technical
- Relative Strength Index (RSI)
- HALO 39.78
- LNTH 32.82
- Support Level
- HALO $47.50
- LNTH $77.01
- Resistance Level
- HALO $69.94
- LNTH $83.60
- Average True Range (ATR)
- HALO 3.52
- LNTH 3.77
- MACD
- HALO -1.49
- LNTH -2.21
- Stochastic Oscillator
- HALO 19.64
- LNTH 13.26
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.